The continued successes of large- and small-scale genome sequencing projects are increasing the number of genomic targets available for drug d- covery at an exponential rate. In addition, a better understanding of molecular mechanisms such as apoptosis, signal transduction, telomere control of ch- mosomes, cytoskeletal development, modulation of stress-related proteins, and cell surface display of antigens by the major histocompatibility complex m- ecules has improved the probability of identifying the most promising genomic targets to counteract disease. As a result, developing and...
The continued successes of large- and small-scale genome sequencing projects are increasing the number of genomic targets available for drug d- covery...
The continued successes of large- and small-scale genome sequencing projects are increasing the number of genomic targets available for drug d- covery at an exponential rate. In addition, a better understanding of molecular mechanisms-such as apoptosis, signal transduction, telomere control of ch- mosomes, cytoskeletal development, modulation of stress-related proteins, and cell surface display of antigens by the major histocompatibility complex m- ecules-has improved the probability of identifying the most promising genomic targets to counteract disease. As a result, developing and...
The continued successes of large- and small-scale genome sequencing projects are increasing the number of genomic targets available for drug d- covery...